Related Experiment Video
Updated: May 4, 2026
10:03
Coronary Progenitor Cells and Soluble Biomarkers in Cardiovascular Prognosis after Coronary Angioplasty
Published on: January 28, 2020
4.9K
A novel cardiac bio-marker: ST2: a review
Marco Matteo Ciccone1, Francesca Cortese, Michele Gesualdo
1Cardiovascular Diseases Section, Department of Emergency and Organ Transplantation (DETO), University of Bari, Bari 70124, Italy. marcomatteo.ciccone@uniba.it.
Molecules (Basel, Switzerland)
|December 17, 2013
Summary
Soluble ST2 (suppression of tumorigenicity 2) shows promise as an early cardiovascular disease marker. Measuring soluble ST2 may improve detection of heart failure and ischemic heart conditions.
Area of Science:
- Biochemistry
- Cardiology
- Biomarkers
Background:
- Cardiovascular diseases (CVD) are a leading global cause of mortality.
- Current biomarkers like BNP, NT-proBNP, and troponins have limitations in accuracy for early CVD detection.
- There is a need for novel biomarkers to identify early-stage CVD and monitor disease progression.
Purpose of the Study:
- To review the potential of soluble ST2 (suppression of tumorigenicity 2) as an early detection marker for cardiovascular diseases.
- To explore the role of soluble ST2 in heart failure (HF) and ischemic heart diseases.
- To assess the clinical utility of soluble ST2 beyond existing biomarkers.
Main Methods:
- Literature review focusing on soluble ST2 as a biomarker.
- Analysis of ST2's role as a decoy receptor for interleukin-33.
- Examination of ST2 induction in mechanically overloaded cardiac myocytes.
- Review of studies measuring blood levels of soluble ST2 in cardiovascular conditions.
Main Results:
- Soluble ST2 is a protein induced in cardiac myocytes under mechanical stress, such as in heart failure or myocardial infarction.
- Its levels in the blood may indicate the onset or worsening of heart failure.
- ST2's mechanism as a decoy receptor suggests its involvement in inflammatory pathways relevant to CVD.
Conclusions:
- Soluble ST2 demonstrates potential as a valuable early diagnostic and prognostic marker for cardiovascular diseases, particularly heart failure and ischemic conditions.
- Further research is warranted to fully elucidate ST2's role and integrate it into clinical practice.
- Measuring soluble ST2 could enhance the early detection and management of CVD, complementing existing biomarkers.
Related Concept Videos
01:19Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers
765
Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
765
01:20Blood Studies for Cardiovascular System I: Cardiac Biomarkers
1.2K
Cardiac biomarkers are enzymes, proteins, and hormones released into the blood when cardiac cells are injured. They are powerful tools for triaging.
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
1.2K
01:19Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations
943
The pathophysiology of Acute Coronary Syndrome [ACD] involves several key processes:The main underlying cause of ACD is atherosclerosis, a chronic inflammatory disease characterized by the buildup of lipid-laden plaques within the coronary arteries.As the atherosclerotic plaque grows in the coronary artery, it may become unstable due to the formation of a lipid-rich core and a thin fibrous cap. Inflammatory cells within the plaque, such as macrophages, secrete enzymes that degrade the...
943
01:27Myocarditis II: Clinical Features and Diagnostic Tests
493
Myocarditis is an inflammation of the heart muscle. The symptoms vary widely, encompassing asymptomatic presentations to severe, acute manifestations.Clinical PresentationAsymptomatic cases: In some instances, myocarditis may be asymptomatic, with the infection resolving without intervention. These cases often go undetected unless discovered incidentally through diagnostic imaging or tests conducted for other reasons.General Early Symptoms: Early symptoms of myocarditis are non-specific and can...
493
01:30Acute Coronary Syndrome III: Diagnostic Studies
495
Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...
495
01:23Mitral Stenosis II: Clinical features and Diagnostic Tests
557
Mitral stenosis is a heart condition in which the mitral valve, which allows blood to flow from the left atrium to the left ventricle, becomes narrowed or stenotic. This narrowing hinders blood flow and leads to clinical symptoms requiring specific medical evaluations and management strategies. The following overview outlines the clinical symptoms, assessments, diagnostic findings, prevention methods, and treatments for mitral stenosis.Clinical ManifestationsDyspnea (shortness of breath): This...
557